Related Experiment Video
Updated: May 6, 2026
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Salinomycin increases chemosensitivity to the effects of doxorubicin in soft tissue sarcomas
Sven-T Liffers1, Daniel J Tilkorn, Ingo Stricker
1Institute of Pathology, Ruhr-University Bochum, Buerkle-de-la-Camp-Platz 1, 44789 Bochum, Germany. sven-thorsten.liffers@rub.de.
Background:
Chemotherapy for soft tissue sarcomas remains unsatisfactory due to their low chemosensitivity. Even the first line chemotherapeutic agent doxorubicin only yields a response rate of 18-29%. The antibiotic salinomycin, a potassium ionophore, has recently been shown to be a potent compound to deplete chemoresistant cells like cancer stem like cells (CSC) in adenocarcinomas. Here, we evaluated the effect of salinomycin on sarcoma cell lines, whereby salinomycin mono- and combination treatment with doxorubicin regimens were analyzed.
Methods:
To evaluate the effect of salinomycin on fibrosarcoma, rhabdomyosarcoma and liposarcoma cell lines, cells were drug exposed in single and combined treatments, respectively. The effects of the corresponding treatments were monitored by cell viability assays, cell cycle analysis, caspase 3/7 and 9 activity assays. Further we analyzed NF-κB activity; p53, p21 and PUMA transcription levels, together with p53 expression and serine 15 phosphorylation.
Results:
The combination of salinomycin with doxorubicin enhanced caspase activation and increased the sub-G1 fraction. The combined treatment yielded higher NF-κB activity, and p53, p21 and PUMA transcription, whereas the salinomycin monotreatment did not cause any significant changes.
Conclusions:
Salinomycin increases the chemosensitivity of sarcoma cell lines - even at sub-lethal concentrations - to the cytostatic drug doxorubicin. These findings support a strategy to decrease the doxorubicin concentration in combination with salinomycin in order to reduce toxic side effects.
Insights
Salinomycin enhances sarcoma cell sensitivity to doxorubicin chemotherapy, even at low doses. This combination therapy may reduce doxorubicin
Area of Science:
- Oncology
- Pharmacology
Background:
- Soft tissue sarcomas exhibit poor response to chemotherapy, with doxorubicin showing limited efficacy (18-29% response rate).
- Salinomycin, a potassium ionophore, has demonstrated potential in eliminating chemoresistant cancer stem-like cells (CSCs) in other cancers.
Purpose of the Study:
- To investigate the efficacy of salinomycin, alone and in combination with doxorubicin, against sarcoma cell lines.
- To assess the impact of salinomycin on doxorubicin's effectiveness in treating soft tissue sarcomas.
Main Methods:
- Fibrosarcoma, rhabdomyosarcoma, and liposarcoma cell lines were treated with salinomycin and doxorubicin, both individually and in combination.
- Evaluated outcomes included cell viability, cell cycle progression, caspase activity (3/7 and 9), NF-κB activity, and transcription/expression levels of p53, p21, and PUMA.
Main Results:
- Combined salinomycin and doxorubicin treatment significantly increased caspase activation and the sub-G1 cell fraction, indicating enhanced apoptosis.
- The combination therapy also elevated NF-κB activity and the transcription of p53, p21, and PUMA.
- Salinomycin monotherapy did not produce significant changes in the tested parameters.
Conclusions:
- Salinomycin potentiates the chemosensitivity of sarcoma cell lines to doxorubicin, even at sub-lethal concentrations.
- This suggests a potential therapeutic strategy using lower doxorubicin doses in combination with salinomycin to mitigate treatment toxicity.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023